Senior Associate

María Cadarso

Maria Cadarso, Legal Litigation, Elzaburu

"Her work often begins before a conflict arises, through contract negotiation and strategic positioning aimed at preserving bargaining power and preventing escalation whenever possible."

Contact Us

Services

Legal and preventive advice

Industrial and Intellectual Property Litigation

+ 5 services

Training

Lawyer

Languages

Spanish · English

Experience

+ 12 years

Maria Cadarso, Legal Litigation, Elzaburu

"Her work often begins before a conflict arises, through contract negotiation and strategic positioning aimed at preserving bargaining power and preventing escalation whenever possible."

Biography

María is an attorney specializing in industrial property law, intellectual property, unfair competition, and related areas, with extensive experience in our Litigation Department. She has advised and represented domestic and international clients in the defense of their rights, both in and out of court. Her experience includes filing out-of-court claims, negotiating settlement agreements, and, when necessary, defending her clients’ rights in court.

Education

She holds a bachelor's degree in Law and Political Science from the Autonomous University of Madrid.
A practicing attorney since 2014.
Master's Degree in Intellectual Property, Industrial Property, and New Technologies from the Autonomous University of Madrid.

Practice Areas

Out-of-court claims, litigation, arbitration, and mediation regarding:

Trademarks, Patents, Industrial Designs
Copyright
Personality Rights and Corporate Reputation
Unfair Competition and Advertising
Contracts for Intangible Assets and Commercial Contracts

Associations

Member of AIPPI and ECTA.

Teaching Experience

She currently teaches courses on Trademarks, Advertising, and Unfair Competition in the Master's Program in Intellectual and Industrial Property at the University of La Rioja (UNIR).

Awards

Legal 500	Patents
Best Lawyers in Spain	Industrial and Intellectual Property
Iberian Lawyer	Finalist in the "IP Lawyer of the Year" category of the "Forty Under 40" awards in 2024 and 2026
Benchmark Litigation Europe	Litigation
IAM Patent 1000	Patent litigation
See more

Name*

Last Name*

Email*

Phone

Position

Company*

Message*

I agree to receive communications from ELZABURU regarding new products, services, and news of interest, including via electronic means. You may withdraw your consent at any time as indicated in the Privacy Policy.

I have read and accept the legal notice and terms of use.*

ELZABURU will process your personal data to respond to and manage your request and/or communication, as well as—if you check the corresponding box—to send you communications about our latest news, services, and other information of interest. You can exercise your data protection rights by contacting protecciondedatos@elzaburu.es and find additional information in our Privacy Policy.

ELZABURU does not engage in collaboration models based on work-for-equity arrangements, nor does it provide its services on a contingency fee basis.

María Cadarso's Latest Publications and Appearances

ELZABURU is once again ranked among the leading patent firms according to IAM Patent 1000

ELZABURU is once again ranked among the leading patent firms according to IAM Patent 1000

Madrid, June 3, 2026. ELZABURU has once again been recognized in the latest edition of IAM Patent 1000, one of the leading international directories in the field of patents, which identifies the most prominent firms and professionals worldwide. IAM Patent 1000 highlights those firms and […]

The Court of Justice confirms that, to obtain a CCP, the “first AC” is the one granted first, even if it is no longer in effect at the time of application

The Court of Justice confirms that, to obtain a CCP, the “first AC” is the one granted first, even if it is no longer in effect at the time of application

Order of the Court of Justice of July 16, 2024, Genmab (C-181/24) Facts The pharmaceutical company Genmab obtained an initial marketing authorization (“MA”) for a medicinal product “A” containing the active ingredient ofatumumab (the “previous MA”). It subsequently revoked that MA. Some time later, Genmab obtained a second MA (the “subsequent MA”) for a new […]

Conditions for granting a CCP for a combination of active ingredients.

Conditions for granting a CCP for a combination of active ingredients.

Judgment of the Court of Justice of December 19, 2024, Teva Finland (C-119/22 and C-149/22) 1. Facts The case arises from applications for a supplementary protection certificate (“SPC”) filed by Merck Sharp & Dohme LLC based on a European patent (“basic patent”) covering a DPP-4 inhibitor active ingredient (sitagliptin) and […]

EU Member States may not apply the “substantive reciprocity” criterion set forth in Article 2.7 of the Berne Convention to works of applied art whose country of origin is not a Member State

EU Member States may not apply the “substantive reciprocity” criterion set forth in Article 2.7 of the Berne Convention to works of applied art whose country of origin is not a Member State

Judgment of the Court of Justice of October 24, 2024, Kwantum (C-227/23) 1. Facts The Swiss furniture manufacturer Vitra holds the intellectual property rights to furniture designs created by Charles and Ray Eames (U.S. nationals), including, among others, the “DSW chair.” Vitra has brought an action against […]

ELZABURU is once again ranked among the leading patent firms according to IAM Patent 1000

ELZABURU is once again ranked among the leading patent firms according to IAM Patent 1000

Madrid, June 3, 2026. ELZABURU has once again been recognized in the latest edition of IAM Patent 1000, one of the leading international directories in the field of patents, which identifies the most prominent firms and professionals worldwide. IAM Patent 1000 highlights those firms and […]

The Court of Justice confirms that, to obtain a CCP, the “first AC” is the one granted first, even if it is no longer in effect at the time of application

The Court of Justice confirms that, to obtain a CCP, the “first AC” is the one granted first, even if it is no longer in effect at the time of application

Order of the Court of Justice of July 16, 2024, Genmab (C-181/24) Facts The pharmaceutical company Genmab obtained an initial marketing authorization (“MA”) for a medicinal product “A” containing the active ingredient ofatumumab (the “previous MA”). It subsequently revoked that MA. Some time later, Genmab obtained a second MA (the “subsequent MA”) for a new […]

Conditions for granting a CCP for a combination of active ingredients.

Conditions for granting a CCP for a combination of active ingredients.

Judgment of the Court of Justice of December 19, 2024, Teva Finland (C-119/22 and C-149/22) 1. Facts The case arises from applications for a supplementary protection certificate (“SPC”) filed by Merck Sharp & Dohme LLC based on a European patent (“basic patent”) covering a DPP-4 inhibitor active ingredient (sitagliptin) and […]

EU Member States may not apply the “substantive reciprocity” criterion set forth in Article 2.7 of the Berne Convention to works of applied art whose country of origin is not a Member State

EU Member States may not apply the “substantive reciprocity” criterion set forth in Article 2.7 of the Berne Convention to works of applied art whose country of origin is not a Member State

Judgment of the Court of Justice of October 24, 2024, Kwantum (C-227/23) 1. Facts The Swiss furniture manufacturer Vitra holds the intellectual property rights to furniture designs created by Charles and Ray Eames (U.S. nationals), including, among others, the “DSW chair.” Vitra has brought an action against […]